Literature DB >> 9014145

Isoniazid-induced inhibition of GABAergic transmission enhances neurosteroid content in the rat brain.

M L Barbaccia1, G Roscetti, M Trabucchi, R H Purdy, M C Mostallino, C Perra, A Concas, G Biggio.   

Abstract

Isoniazid (375 mg/kg, s.c.), a drug that decreases GABAA receptor-mediated transmission, elicited a time-dependent increase of neuroactive steroid (pregnenolone, progesterone and allotetrahydrodeoxycorticosterone) concentrations in rat brain and plasma. This treatment also time-dependently increased the plasma concentration of corticosterone. Brain and plasma neuroactive steroid levels peaked between 40 and 120 min after isoniazid administration, respectively, and returned to control values by 5 hr. Acute foot shock stress mimicked the effect of isoniazid by increasing in a time-dependent manner the same neuroactive steroids both in brain and plasma. Abecarnil (0.3 mg/kg, i.p.), a beta-carboline derivative with anxiolytic properties, antagonized the effect of both isoniazid and foot shock on brain and plasma neuroactive steroids and on plasma corticosterone level. These data indicate that an inhibition of central GABAergic transmission enhances the concentrations of THDOC and its precursors pregnenolone and progesterone in the rat brain and plasma as well as the plasma levels of corticosterone. This finding suggests that GABA exerts a tonic inhibitory action on the mechanisms involved in the regulation of the synthesis and release of these neuroactive steroids in the central nervous system and plasma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9014145     DOI: 10.1016/s0028-3908(96)00067-6

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  8 in total

1.  Neurosteroid modulation of GABAergic neurotransmission in the central amygdala: a role for NMDA receptors.

Authors:  Chunsheng Wang; Christine E Marx; A Leslie Morrow; Wilkie A Wilson; Scott D Moore
Journal:  Neurosci Lett       Date:  2007-01-05       Impact factor: 3.046

Review 2.  Stress, ethanol, and neuroactive steroids.

Authors:  Giovanni Biggio; Alessandra Concas; Paolo Follesa; Enrico Sanna; Mariangela Serra
Journal:  Pharmacol Ther       Date:  2007-05-08       Impact factor: 12.310

Review 3.  Allopregnanolone modulation of HPA axis function in the adult rat.

Authors:  Giovanni Biggio; Maria Giuseppina Pisu; Francesca Biggio; Mariangela Serra
Journal:  Psychopharmacology (Berl)       Date:  2014-09       Impact factor: 4.530

4.  Targeting neurosteroid synthesis as a therapy for schizophrenia-related alterations induced by early psychosocial stress.

Authors:  Roberto Frau; Federico Abbiati; Valentina Bini; Alberto Casti; Donatella Caruso; Paola Devoto; Marco Bortolato
Journal:  Schizophr Res       Date:  2015-05-18       Impact factor: 4.939

5.  Effects of acute progesterone administration upon responses to acute psychosocial stress in men.

Authors:  Emma Childs; Nicholas T Van Dam; Harriet de Wit
Journal:  Exp Clin Psychopharmacol       Date:  2010-02       Impact factor: 3.157

6.  gamma-Aminobutyric acid, acting through gamma -aminobutyric acid type A receptors, inhibits the biosynthesis of neurosteroids in the frog hypothalamus.

Authors:  J L Do-Rego; G A Mensah-Nyagan; D Beaujean; D Vaudry; W Sieghart; V Luu-The; G Pelletier; H Vaudry
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

Review 7.  The relevance of neuroactive steroids in schizophrenia, depression, and anxiety disorders.

Authors:  Erin M MacKenzie; John Odontiadis; Jean-Michel Le Mellédo; Trevor I Prior; Glen B I Baker
Journal:  Cell Mol Neurobiol       Date:  2007-08       Impact factor: 5.046

8.  Regulation of neurosteroid biosynthesis by neurotransmitters and neuropeptides.

Authors:  Jean Luc Do Rego; Jae Young Seong; Delphine Burel; Jerôme Leprince; David Vaudry; Van Luu-The; Marie-Christine Tonon; Kazuyoshi Tsutsui; Georges Pelletier; Hubert Vaudry
Journal:  Front Endocrinol (Lausanne)       Date:  2012-01-24       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.